Takeda's Zasocitinib Delivers in Phase 3 for Hard-to-Treat Psoriasis
Takeda calls phase 3 results for oral TYK2 inhibitor zasocitinib 'top-notch' in difficult-to-treat psoriasis, positioning a pill against biologics.
Topic
Tyk2 Inhibitor
Topic
Tyk2 Inhibitor
Alumis reports 48-week psoriasis symptom data
Alumis has reported 48-week psoriasis symptom data from its TYK2 inhibitor program, extending durability evidence well past the s…
Icotrokinra Sustains High-Impact Site Clearance at 2 Years
Two-year ICONIC-TOTAL extension data show icotrokinra sustains clearance of high-impact psoriasis sites — scalp, face, palms, sol…
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trial
Phase 3 head-to-head data show once-daily zasocitinib achieved superior skin clearance versus deucravacitinib in plaque psoriasis…
Zasocitinib Beats Deucravacitinib Head-to-Head in Phase 3 Psoriasis
In the Phase 3 LATITUDE Atlas head-to-head trial, zasocitinib achieved PASI-100 in 36.5% of patients at Week 16 versus 13.9% for…
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Trial
Zasocitinib showed superior efficacy versus deucravacitinib in Phase 3 head-to-head psoriasis data, with rapid, durable clearance…
Zasocitinib Clears Psoriasis at Hardest-to-Treat Sites in Once-Daily Pill
Once-daily oral TYK2 inhibitor zasocitinib cleared psoriasis at the scalp, palms, soles and nails — sites where topicals and curr…